Defendant
1 case as defendant.
Zydus Lifesciences Ltd. is a publicly traded Indian multinational pharmaceutical company headquartered in Ahmedabad, India. Founded in 1952 as Cadila Laboratories, the company was restructured in 1995 and later renamed from Cadila Healthcare Limited to Zydus Lifesciences Ltd. in 2022. The company trades on India's BSE and NSE exchanges under the ticker ZYDUSLIFE. Zydus Lifesciences is a large operating company with over 25,000 employees and reported revenues of approximately US$2.5 billion for the fiscal year ending in March 2025.
The company operates as a fully integrated global healthcare provider, primarily engaged in the manufacturing of generic drugs. Its product portfolio is extensive, covering formulations, active pharmaceutical ingredients (APIs), vaccines, biosimilars, animal health products, and consumer wellness products. Zydus develops and manufactures a wide range of pharmaceuticals, including diagnostics, herbal products, and skincare. The company has a significant presence in the United States through its subsidiary, Zydus Pharmaceuticals (USA) Inc., which markets hundreds of products and has over 280 approved Abbreviated New Drug Applications (ANDAs) from the USFDA.
Based on its litigation history, Zydus Lifesciences is an operating company that defends its market activities. The company has been a defendant in all two of its tracked U.S. patent cases and has not appeared as a plaintiff. This pattern is typical for a generic drug manufacturer, which often faces patent infringement lawsuits from brand-name pharmaceutical companies when seeking to market generic versions of their drugs. The cases are filed in the districts of Delaware and New Jersey, common venues for pharmaceutical patent disputes.
The tracked cases reflect Zydus's position as a generic drug manufacturer being challenged by brand-name drug companies. The defendants in these suits include Zydus and its U.S. subsidiary, Zydus Pharmaceuticals (USA) Inc. In Astellas Pharma Inc. et al. v. Zydus Pharmaceuticals (USA) Inc. et al. (2024) and Veloxis Pharmaceuticals AS v. Zydus Cadila et al. (2026), Zydus is defending against infringement claims brought by other pharmaceutical corporations. This type of litigation is a standard part of the business process for companies introducing generic equivalents of patented medicines in the U.S. market.
This case has been consolidated with case 3:24-cv-09403 and appears to be ongoing. An amended complaint including US patent 12161628 was filed on January 3, 2025.